GenMark secures EUA for multiplex test

By staff writers

October 9, 2020 -- The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to GenMark Diagnostics for its ePlex respiratory pathogen panel 2 (RP2) test. The test provides results for more than 20 viruses and bacteria that can cause serious respiratory infections including COVID-19, the flu, bronchitis, and the common cold.

In less than two hours, the ePlex RP2 test can identify or rule out the responsible pathogen or pathogens to ensure proper treatment. The ePlex RP2 panel is designed for use with the firm's ePlex system, along with the ePlex RP panel and blood culture identification (BCID) panels (gram-positive, gram-negative, and fungal pathogens).

The ePlex RP2 panel also has the CE Mark.

GenMark releases new rapid respiratory infection panel test
GenMark Diagnostics has released a new rapid result, multiple-virus panel test that can identify more than 20 pathogens, including SARS-CoV-2.
Molecular testing and COVID-19: Where are we now?
As the COVID-19 pandemic accelerates, attention has been focused on how to effectively scale up the diagnostic testing that is needed to correctly manage...

Copyright © 2020

Last Updated ls 10/9/2020 3:38:35 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current